{"id":5845,"date":"2026-06-25T17:38:25","date_gmt":"2026-06-25T17:38:25","guid":{"rendered":"https:\/\/ceo.com.pl\/en\/?p=5845"},"modified":"2026-06-25T17:38:32","modified_gmt":"2026-06-25T17:38:32","slug":"polands-prescription-drug-market-grows-on-higher-prices-not-more-prescriptions-29064","status":"publish","type":"post","link":"https:\/\/ceo.com.pl\/en\/polands-prescription-drug-market-grows-on-higher-prices-not-more-prescriptions-29064\/","title":{"rendered":"Poland\u2019s Prescription Drug Market Grows on Higher Prices, Not More Prescriptions"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">In 2025, Poles filled almost the same number of prescriptions as a year earlier, but paid 13.1% more for them. Prescription drug sales reached PLN 33.4bn, while reimbursement from the National Health Fund (NFZ) grew faster than patients\u2019 co-payments \u2014 its share of the cost of purchased medicines rose to 45.9%. One category remains the main driver of growth: drugs for the alimentary tract and metabolism.<\/p>\n\n\n\n<div class=\"ceo-rx-article\">\n<style>\n.ceo-rx-article{--navy:#131F49;--navy2:#1a3a6c;--amber:#e67a2d;--ink:#1f2433;--muted:#5b6477;--line:#e4e7ee;--bg:#f6f7fa;font-family:Georgia,'Times New Roman',serif;color:var(--ink);max-width:860px;margin:0 auto;line-height:1.7;font-size:18px;padding:0 4px}\n.ceo-rx-article *{box-sizing:border-box}\n.ceo-rx-kicker{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;font-size:12px;font-weight:700;letter-spacing:.12em;text-transform:uppercase;color:#fff;background:var(--navy);padding:7px 13px;border-radius:3px;margin-bottom:18px}\n.ceo-rx-article h1{font-size:34px;line-height:1.2;color:var(--navy);margin:6px 0 18px;font-weight:700}\n.ceo-rx-article h2{font-size:25px;color:var(--navy);margin:42px 0 14px;font-weight:700;line-height:1.25}\n.ceo-rx-lead{font-size:20px;color:var(--ink);background:var(--bg);border-left:4px solid var(--amber);padding:16px 20px;margin:0 0 26px;border-radius:0 4px 4px 0}\n.ceo-rx-article p{margin:0 0 16px}\n.ceo-rx-kpis{display:grid;grid-template-columns:repeat(4,1fr);gap:14px;margin:28px 0}\n.ceo-rx-kpi{background:#fff;border:1px solid var(--line);border-top:3px solid var(--amber);border-radius:6px;padding:16px 14px;text-align:center}\n.ceo-rx-kpi .v{font-size:30px;font-weight:700;color:var(--navy);line-height:1;font-family:Georgia,serif}\n.ceo-rx-kpi .l{font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;font-size:12.5px;color:var(--muted);margin-top:9px;line-height:1.35}\n.ceo-rx-chartwrap{background:#fff;border:1px solid var(--line);border-radius:8px;padding:20px 18px 14px;margin:26px 0}\n.ceo-rx-chartwrap .ct{font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;font-size:14px;font-weight:700;color:var(--navy);margin-bottom:4px}\n.ceo-rx-chartwrap .cs{font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;font-size:12.5px;color:var(--muted);margin-bottom:14px}\n.ceo-rx-canvas-box{position:relative;width:100%;height:340px}\n.ceo-rx-table{width:100%;border-collapse:collapse;margin:24px 0;font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;font-size:15px}\n.ceo-rx-table th{background:var(--navy);color:#fff;text-align:left;padding:11px 13px;font-weight:600;font-size:13.5px}\n.ceo-rx-table th.num,.ceo-rx-table td.num{text-align:right}\n.ceo-rx-table td{padding:10px 13px;border-bottom:1px solid var(--line)}\n.ceo-rx-table tr:nth-child(even) td{background:var(--bg)}\n.ceo-rx-table tr.hi td{background:#fdf1e7}\n.ceo-rx-callout{background:var(--navy);border-radius:8px;padding:26px 28px;margin:34px 0}\n.ceo-rx-callout p{color:#ffffff !important;margin:0 0 12px;font-size:18.5px;line-height:1.6}\n.ceo-rx-callout p:last-child{margin-bottom:0}\n.ceo-rx-callout strong{color:var(--amber)}\n.ceo-rx-takeaways{background:var(--bg);border:1px solid var(--line);border-radius:8px;padding:22px 26px;margin:30px 0}\n.ceo-rx-takeaways h3{font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;font-size:13px;letter-spacing:.08em;text-transform:uppercase;color:var(--amber);margin:0 0 14px}\n.ceo-rx-takeaways ul{margin:0;padding:0;list-style:none}\n.ceo-rx-takeaways li{position:relative;padding:0 0 11px 26px;font-size:16.5px;line-height:1.5}\n.ceo-rx-takeaways li:last-child{padding-bottom:0}\n.ceo-rx-takeaways li:before{content:\"\";position:absolute;left:0;top:9px;width:9px;height:9px;background:var(--amber);border-radius:2px;transform:rotate(45deg)}\n.ceo-rx-source{font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;font-size:13px;color:var(--muted);border-top:1px solid var(--line);padding-top:16px;margin-top:34px;font-style:italic}\n@media(max-width:680px){.ceo-rx-article{font-size:17px}.ceo-rx-article h1{font-size:27px}.ceo-rx-kpis{grid-template-columns:repeat(2,1fr)}.ceo-rx-kpi .v{font-size:26px}.ceo-rx-canvas-box{height:300px}.ceo-rx-table{font-size:13.5px}.ceo-rx-table th,.ceo-rx-table td{padding:8px 9px}}\n<\/style>\n\n<span class=\"ceo-rx-kicker\">Pharmaceutical market \u00b7 Statistics Poland 2025<\/span>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ceo.com.pl\/en\/polands-prescription-drug-market-grows-on-higher-prices-not-more-prescriptions-29064\/#Prescription_drug_market_grows_to_PLN_334bn_The_National_Health_Fund_is_covering_an_increasing_share_of_the_bill\" >Prescription drug market grows to PLN 33.4bn. The National Health Fund is covering an increasing share of the bill<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ceo.com.pl\/en\/polands-prescription-drug-market-grows-on-higher-prices-not-more-prescriptions-29064\/#The_bill_is_rising_and_the_NFZ_is_paying_more\" >The bill is rising, and the NFZ is paying more<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ceo.com.pl\/en\/polands-prescription-drug-market-grows-on-higher-prices-not-more-prescriptions-29064\/#Metabolic_drugs_overtake_cardiovascular_medicines\" >Metabolic drugs overtake cardiovascular medicines<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ceo.com.pl\/en\/polands-prescription-drug-market-grows-on-higher-prices-not-more-prescriptions-29064\/#Regional_picture_Lodzkie_leads_Podkarpackie_trails\" >Regional picture: \u0141\u00f3dzkie leads, Podkarpackie trails<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ceo.com.pl\/en\/polands-prescription-drug-market-grows-on-higher-prices-not-more-prescriptions-29064\/#What_this_means_for_the_market\" >What this means for the market<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Prescription_drug_market_grows_to_PLN_334bn_The_National_Health_Fund_is_covering_an_increasing_share_of_the_bill\"><\/span>Prescription drug market grows to PLN 33.4bn. The National Health Fund is covering an increasing share of the bill<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>The latest data from Statistics Poland, based on the Ministry of Health\u2019s Medical Information System, show a market expanding in value despite an almost unchanged volume. Pharmacies and pharmacy outlets filled 515.6 million prescriptions in 2025 \u2014 2.3 million, or 0.4%, more than a year earlier. Since the number of prescriptions has effectively remained flat, the entire increase in value reflects higher unit prices and a shift in the sales mix towards more expensive therapies.<\/p>\n\n<div class=\"ceo-rx-kpis\">\n  <div class=\"ceo-rx-kpi\"><div class=\"v\">PLN 33.4bn<\/div><div class=\"l\">value of prescription drug sales (+13.1% year on year)<\/div><\/div>\n  <div class=\"ceo-rx-kpi\"><div class=\"v\">45.9%<\/div><div class=\"l\">NFZ reimbursement share of medicine costs<\/div><\/div>\n  <div class=\"ceo-rx-kpi\"><div class=\"v\">515.6m<\/div><div class=\"l\">prescriptions filled (+0.4% year on year)<\/div><\/div>\n  <div class=\"ceo-rx-kpi\"><div class=\"v\">97.8%<\/div><div class=\"l\">of prescriptions issued electronically<\/div><\/div>\n<\/div>\n\n<h2><span class=\"ez-toc-section\" id=\"The_bill_is_rising_and_the_NFZ_is_paying_more\"><\/span>The bill is rising, and the NFZ is paying more<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Of the PLN 33.4bn in sales value, patients paid PLN 18.1bn out of pocket \u2014 10.9% more than in 2024. Reimbursement from the National Health Fund reached PLN 15.3bn and rose by 15.8%, clearly faster than private co-payments. This extends a multi-year trend: between 2022 and 2025, total prescription drug sales increased by 52.8%, but NFZ reimbursement rose by 78.7%, while patient payments increased by only 36.1%. As a result, the share of public funds in financing prescription medicines increased from 39.3% in 2022 to 45.9% in 2025.<\/p>\n\n<p>Per capita, Poland spent PLN 893 on prescription medicines, PLN 106 more than a year earlier. Of this total, PLN 410 came from NFZ reimbursement and PLN 483 from private co-payments. This means that patients still finance the majority \u2014 54.1% of the value of medicines purchased \u2014 although this share is steadily declining.<\/p>\n\n<div class=\"ceo-rx-chartwrap\">\n  <div class=\"ct\">Prescription drug expenditure per capita in Poland<\/div>\n  <div class=\"cs\">NFZ reimbursement and patient co-payments, PLN, 2022\u20132025<\/div>\n  <div class=\"ceo-rx-canvas-box\"><canvas id=\"ceoRxPercap\"><\/canvas><\/div>\n<\/div>\n\n<h2><span class=\"ez-toc-section\" id=\"Metabolic_drugs_overtake_cardiovascular_medicines\"><\/span>Metabolic drugs overtake cardiovascular medicines<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>The most significant market change is taking place in the sales structure. In 2025, medicines used to treat disorders of the alimentary tract and metabolism, including products that help reduce excess weight, accounted for the largest share of total sales value at 24.8%. The category has been advancing steadily: its share stood at 17.5% in 2022, 18.9% in 2023 and 21.4% in 2024, before reaching almost one-quarter of the market in 2025.<\/p>\n\n<div class=\"ceo-rx-chartwrap\">\n  <div class=\"ct\">Share of the \u201calimentary tract and metabolism\u201d group in sales value<\/div>\n  <div class=\"cs\">Percentage of total prescription drug sales value, 2022\u20132025<\/div>\n  <div class=\"ceo-rx-canvas-box\" style=\"height:280px\"><canvas id=\"ceoRxTrend\"><\/canvas><\/div>\n<\/div>\n\n<p>Cardiovascular medicines ranked second, with a 17.7% share. Until 2023, this group had led the ranking, but it was overtaken by metabolic medicines in 2024, and the gap between the two categories continues to widen. Drugs for the nervous system ranked third at 12.8%. The only change among the leading groups compared with the previous year was the rise of anti-infective medicines \u2014 their share increased from 5.5% to 7.2%, moving them from seventh to fifth place.<\/p>\n\n<div class=\"ceo-rx-chartwrap\">\n  <div class=\"ct\">Prescription drug sales structure by ATC group<\/div>\n  <div class=\"cs\">Share of sales value, 2025, %<\/div>\n  <div class=\"ceo-rx-canvas-box\" style=\"height:420px\"><canvas id=\"ceoRxAtc\"><\/canvas><\/div>\n<\/div>\n\n<h2><span class=\"ez-toc-section\" id=\"Regional_picture_Lodzkie_leads_Podkarpackie_trails\"><\/span>Regional picture: \u0141\u00f3dzkie leads, Podkarpackie trails<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>The value of medicine sales per inhabitant differs by more than one-quarter between regions. The highest figure was recorded in the \u0141\u00f3dzkie province at PLN 1,005 per person, including PLN 484 in reimbursement. Mazowieckie ranked second at PLN 970 and stood out for the highest private co-payments in the country, at PLN 573 per inhabitant. At the other end of the scale was Podkarpackie, with the lowest sales value at PLN 748 and the lowest reimbursement level at PLN 349. Residents of Warmi\u0144sko-Mazurskie paid the least from their own pockets, at PLN 397.<\/p>\n\n<table class=\"ceo-rx-table\">\n  <thead><tr><th>Province<\/th><th class=\"num\">Sales per capita (PLN)<\/th><th class=\"num\">NFZ reimbursement (PLN)<\/th><th class=\"num\">Patient co-payment (PLN)<\/th><\/tr><\/thead>\n  <tbody>\n    <tr class=\"hi\"><td>\u0141\u00f3dzkie<\/td><td class=\"num\">1,005<\/td><td class=\"num\">484<\/td><td class=\"num\">521<\/td><\/tr>\n    <tr><td>Mazowieckie<\/td><td class=\"num\">970<\/td><td class=\"num\">397<\/td><td class=\"num\">573<\/td><\/tr>\n    <tr><td>Pomorskie<\/td><td class=\"num\">909<\/td><td class=\"num\">416<\/td><td class=\"num\">493<\/td><\/tr>\n    <tr><td>Kujawsko-Pomorskie<\/td><td class=\"num\">906<\/td><td class=\"num\">446<\/td><td class=\"num\">460<\/td><\/tr>\n    <tr><td>\u015al\u0105skie<\/td><td class=\"num\">900<\/td><td class=\"num\">428<\/td><td class=\"num\">472<\/td><\/tr>\n    <tr><td>Wielkopolskie<\/td><td class=\"num\">900<\/td><td class=\"num\">418<\/td><td class=\"num\">482<\/td><\/tr>\n    <tr><td>Dolno\u015bl\u0105skie<\/td><td class=\"num\">886<\/td><td class=\"num\">409<\/td><td class=\"num\">477<\/td><\/tr>\n    <tr><td>Zachodniopomorskie<\/td><td class=\"num\">884<\/td><td class=\"num\">425<\/td><td class=\"num\">459<\/td><\/tr>\n    <tr><td>\u015awi\u0119tokrzyskie<\/td><td class=\"num\">877<\/td><td class=\"num\">416<\/td><td class=\"num\">461<\/td><\/tr>\n    <tr><td>Ma\u0142opolskie<\/td><td class=\"num\">876<\/td><td class=\"num\">388<\/td><td class=\"num\">488<\/td><\/tr>\n    <tr><td>Lubelskie<\/td><td class=\"num\">866<\/td><td class=\"num\">403<\/td><td class=\"num\">463<\/td><\/tr>\n    <tr><td>Podlaskie<\/td><td class=\"num\">860<\/td><td class=\"num\">383<\/td><td class=\"num\">477<\/td><\/tr>\n    <tr><td>Lubuskie<\/td><td class=\"num\">832<\/td><td class=\"num\">390<\/td><td class=\"num\">442<\/td><\/tr>\n    <tr><td>Opolskie<\/td><td class=\"num\">815<\/td><td class=\"num\">395<\/td><td class=\"num\">420<\/td><\/tr>\n    <tr><td>Warmi\u0144sko-Mazurskie<\/td><td class=\"num\">784<\/td><td class=\"num\">387<\/td><td class=\"num\">397<\/td><\/tr>\n    <tr class=\"hi\"><td>Podkarpackie<\/td><td class=\"num\">748<\/td><td class=\"num\">349<\/td><td class=\"num\">399<\/td><\/tr>\n  <\/tbody>\n<\/table>\n\n<p>\u0141\u00f3dzkie also led in the number of prescriptions per inhabitant, at 15.8 per year, while Podkarpackie ranked last at 12.5, against a national average of 13.8. Much wider differences emerge at county level \u2014 from 3.2 prescriptions per inhabitant in Przemy\u015bl County to 31.1 in Zamo\u015b\u0107. This is largely the result of the service function of county-level cities: pharmacies in Zamo\u015b\u0107, Krosno and Tarn\u00f3w serve patients from surrounding, less urbanised counties, which inflates the local indicator.<\/p>\n\n<div class=\"ceo-rx-callout\">\n  <p>Electronic prescriptions accounted for <strong>97.8%<\/strong> of all prescriptions filled \u2014 0.4 percentage points more than a year earlier. Differences between provinces have virtually disappeared, with a spread of just 1.2 percentage points.<\/p>\n  <p>The e-prescription system, introduced only in 2020, already covered <strong>94.4%<\/strong> of the market after one year. The digitalisation of prescribing is now, in practice, complete in Poland.<\/p>\n<\/div>\n\n<div class=\"ceo-rx-takeaways\">\n  <h3><span class=\"ez-toc-section\" id=\"What_this_means_for_the_market\"><\/span>What this means for the market<span class=\"ez-toc-section-end\"><\/span><\/h3>\n  <ul>\n    <li>The market is growing in value (+13.1%), not in volume (+0.4% prescriptions) \u2014 higher prices and the treatment mix, rather than a larger number of patients, are driving growth.<\/li>\n    <li>The financing burden is shifting towards public funds: NFZ reimbursement is growing faster than private co-payments, reaching 45.9% of the total and continuing to rise.<\/li>\n    <li>Metabolic drugs, including medicines for the alimentary tract and weight management, are the fastest-growing segment \u2014 rising from 17.5% of the market in 2022 to 24.8% in 2025, overtaking the former leader, cardiovascular medicines.<\/li>\n    <li>The digitalisation of prescriptions is now an established reality at 97.8%, completing an important stage in the modernisation of Poland\u2019s medicine distribution system.<\/li>\n  <\/ul>\n<\/div>\n\n<p class=\"ceo-rx-source\">Source: Ministry of Health Medical Information System; Statistics Poland publication \u201cPrescription Drug Sales in 2025\u201d (25 June 2026). Own analysis based on data from the Statistics Poland publication \u201cPrescription Drug Sales in 2025\u201d.<\/p>\n\n<script class=\"nowprocket\" data-cfasync=\"false\" data-no-minify=\"1\" src=\"https:\/\/cdnjs.cloudflare.com\/ajax\/libs\/Chart.js\/4.4.1\/chart.umd.min.js\"><\/script>\n<script class=\"nowprocket\" data-cfasync=\"false\" data-no-minify=\"1\">\n(function(){\n  var NAVY='#1a3a6c', NAVY_D='#131F49', AMBER='#e67a2d', AMBER_L='#f0a868', GREY='#aab3c4', LINE='#e4e7ee';\n  var tries=0;\n  var timer=setInterval(function(){\n    tries++;\n    if(typeof Chart==='undefined'){ if(tries>100){clearInterval(timer);} return; }\n    clearInterval(timer);\n    try{ render(); }catch(e){}\n  },100);\n\n  function enFmt(v){ return v; }\n\n  function render(){\n    Chart.defaults.font.family=\"-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif\";\n    Chart.defaults.font.size=12;\n    Chart.defaults.color='#5b6477';\n\n    \/\/ Chart 1 \u2014 per-capita stacked, 2022\u20132025\n    var c1=document.getElementById('ceoRxPercap');\n    if(c1) new Chart(c1,{type:'bar',data:{\n      labels:['2022','2023','2024','2025'],\n      datasets:[\n        {label:'NFZ reimbursement',data:[227,280,353,410],backgroundColor:NAVY_D,maxBarThickness:60,borderRadius:{topLeft:0,topRight:0}},\n        {label:'Patient co-payments',data:[352,413,434,483],backgroundColor:AMBER,maxBarThickness:60,borderRadius:4}\n      ]},options:{responsive:true,maintainAspectRatio:false,plugins:{legend:{position:'bottom',labels:{boxWidth:13,padding:16}},tooltip:{callbacks:{label:function(ctx){return ctx.dataset.label+': PLN '+enFmt(ctx.parsed.y);}}}},scales:{x:{stacked:true,grid:{display:false}},y:{stacked:true,beginAtZero:true,ticks:{callback:function(v){return 'PLN '+v;}},grid:{color:LINE}}}}});\n\n    \/\/ Chart 2 \u2014 A-group share trend\n    var c2=document.getElementById('ceoRxTrend');\n    if(c2) new Chart(c2,{type:'line',data:{\n      labels:['2022','2023','2024','2025'],\n      datasets:[{label:'Share of sales',data:[17.5,18.9,21.4,24.8],borderColor:AMBER,backgroundColor:'rgba(230,122,45,0.12)',borderWidth:3,fill:true,tension:0.25,pointRadius:5,pointBackgroundColor:AMBER,pointBorderColor:'#fff',pointBorderWidth:2}]\n    },options:{responsive:true,maintainAspectRatio:false,plugins:{legend:{display:false},tooltip:{callbacks:{label:function(ctx){return enFmt(ctx.parsed.y)+'% of the market';}}}},scales:{y:{beginAtZero:false,suggestedMin:15,suggestedMax:27,ticks:{callback:function(v){return v+'%';}},grid:{color:LINE}},x:{grid:{display:false}}}}});\n\n    \/\/ Chart 3 \u2014 ATC groups, 2025\n    var c3=document.getElementById('ceoRxAtc');\n    if(c3) new Chart(c3,{type:'bar',data:{\n      labels:['Alimentary tract and metabolism','Cardiovascular system','Nervous system','Respiratory system','Anti-infectives','Blood and blood-forming organs','Genitourinary system and hormones','Musculoskeletal system','Antineoplastic and immunomodulating agents','Dermatology'],\n      datasets:[{label:'Share',data:[24.8,17.7,12.8,7.9,7.2,6.9,5.6,4.3,2.4,2.3],\n        backgroundColor:function(c){return c.dataIndex===0?AMBER:NAVY;},borderRadius:4,maxBarThickness:26}]\n    },options:{indexAxis:'y',responsive:true,maintainAspectRatio:false,plugins:{legend:{display:false},tooltip:{callbacks:{label:function(ctx){return enFmt(ctx.parsed.x)+'% of sales value';}}}},scales:{x:{beginAtZero:true,ticks:{callback:function(v){return v+'%';}},grid:{color:LINE}},y:{grid:{display:false}}}}});\n  }\n})();\n<\/script>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>In 2025, Poles filled almost the same number of prescriptions as a year earlier, but paid 13.1% more for them. Prescription drug sales reached PLN 33.4bn, while reimbursement from the National Health Fund (NFZ) grew faster than patients\u2019 co-payments \u2014 its share of the cost of purchased medicines rose to 45.9%. One category remains the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"Poland\u2019s prescription drug market reached PLN 33.4 billion in 2025 \u2014 up 13.1% year on year \u2014 even though the number of prescriptions filled was almost unchanged.\n\nPharmacies filled 515.6 million prescriptions, only 0.4% more than in 2024. This suggests that market growth was driven mainly by higher prices and a shift towards more expensive therapies.\n\nPatients paid PLN 18.1 billion from their own pockets, while NFZ reimbursement rose faster, reaching PLN 15.3 billion and covering 45.9% of total prescription medicine costs.\n\nThe biggest change is in the market structure. Medicines for the alimentary tract and metabolism, including treatments linked to weight management, became the largest category, accounting for 24.8% of sales value \u2014 ahead of cardiovascular drugs.\n\nRead more: [link]\n\n#Poland #Healthcare #Pharmaceuticals #NFZ #PrescriptionDrugs #HealthEconomy #StatisticsPoland\n","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2656],"tags":[2690,186,2828,187,64,2732,3016],"class_list":["post-5845","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-medicine","tag-gap","tag-medicine","tag-nfz","tag-pharmacies","tag-poland","tag-ranking","tag-tarnow"],"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/posts\/5845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/comments?post=5845"}],"version-history":[{"count":0,"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/posts\/5845\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/media\/5846"}],"wp:attachment":[{"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/media?parent=5845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/categories?post=5845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ceo.com.pl\/en\/wp-json\/wp\/v2\/tags?post=5845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}